Background. Noroviruses are the most common cause of gastroenteritis in the United States. An understanding of the infectious dose of these viruses is important for risk assessment studies.
Human noroviruses are the most common cause of gastroenteritis in the United States, where the infection causes a significant health burden [1, 2] . The inability to propagate human noroviruses in vitro and the lack of a readily available small animal model has led to the use of experimental human infection models to study viral pathogenesis and immunity [3] [4] [5] [6] [7] [8] . Many of these studies have used the prototypical human norovirus, Norwalk virus, as the challenge virus.
Histoblood group antigens (HBGAs) are glycans present on epithelial cells and in body secretions. Their expression is determined genetically by a number of different enzymes [9] , including fucosyl transferase 2 (FUT2). Persons who do not express a functional FUT2 enzyme are naturally resistant to infection with Norwalk virus, even at high dosages [10, 11] . We sought to determine the 50% human infectious dose (HID 50 ) of Norwalk virus in susceptible healthy adults (ie, those with a functional FUT2 enzyme) and to evaluate the effect of dose on disease expression.
MATERIALS AND METHODS

Study Design
The study was a randomized, double-blind, placebocontrolled evaluation of different dosages of Norwalk virus. Subjects were enrolled into 1 of 5 groups between September 2004 and October 2011. Each group was enrolled sequentially and contained up to 12 subjects. The first 4 groups were randomized 5:1 to receive virus or placebo (sterile water). The virus inoculum dosages used for groups 1 to 4 were 4800, 48, 4.8, and 0.48 reverse transcription polymerase chain reaction (RT-PCR) units, respectively. The last group (group 5) was randomized 1:2 to receive 4.8 or 0.48 RT-PCR units of Norwalk virus; placebo was not used for this group because of the low infection frequency observed for group 4 (ie, 0.48 RT-PCR units). The clinical protocol was reviewed and approved by the institutional review boards of the Baylor College of Medicine and The Methodist Hospital, and written informed consent was obtained from each study participant. The study was registered at ClinicalTrials.gov (NCT00138476). Parts of this study have been described in previous publications [12] [13] [14] [15] [16] .
Virus Inoculum
The derivation of the Norwalk virus challenge pool (lot 42 399) has been described previously [13, 17] . Following its preparation, the challenge pool was stored at <−70°C in individual 1-mL aliquots until the day of challenge. The titer of undiluted virus inoculum was initially determined to be 120 000 RT-PCR units by most probable number (MPN) RT-PCR [18] . Subsequent studies using the real-time quantitative RT-PCR assay described below demonstrated that 1 RT-PCR unit of Norwalk virus as determined by MPN RT-PCR contained approximately 400 genomic equivalents (gEq). On the day of virus challenge, a 1-mL vial of the pool containing 120 000 RT-PCR units of virus/mL was thawed and serially diluted in sterile water to obtain the final inoculum dosage for administration. The inoculum was stored on wet ice until administered within several hours of preparation. The dosage range was 0.48-4800 RT-PCR units of Norwalk virus and was administered in a 2-mL volume.
Study Participants
Healthy adults (18-50 years of age) who provided informed consent were screened for eligibility within 4 weeks of virus inoculation. Eligible subjects were secretor positive, had no serious chronic diseases, passed screening laboratory studies (liver and renal function, blood counts, hepatitis and HIV serology), had no history of nonbacterial gastroenteritis within 3 months of inoculation and had negative fecal screening studies for bacterial and protozoal enteric pathogens within 28 days of inoculation, were not exposed to persons at high risk of more severe norovirus infection (including immunocompromised persons, children, and elderly), and did not have jobs identified with a significant risk of transmission to others at risk (eg, food handlers, healthcare workers, airline workers). Persons of blood group B or AB were excluded from enrollment for group 5 only. Study participants were required to pass a test showing an understanding of the protocol.
Challenge Study
Study participants were admitted in groups of 2-6 persons to the General Clinical Research Center (GCRC) at Baylor College of Medicine at The Methodist Hospital on the day of inoculation (day 0). Each subject drank 500 mg sodium bicarbonate in 120 mL water, followed 2 minutes later by 2 mL of the virus inoculum or placebo and then 5 minutes later by 2 sodium bicarbonate (650 mg each) tablets with 120 mL of water. Symptoms were evaluated every 4 hours (while the subjects were awake) for the duration of the GCRC stay, and all fecal samples were collected as described previously [13] . In addition, vomitus samples were collected while the subjects were in the GCRC. The subjects remained in the challenge unit for a minimum of 96 hours. Criteria for discharge included no vomiting or watery stools for at least 18 hours. After discharge, all fecal samples were collected through day 21 and then weekly thereafter for up to 8 weeks postinoculation. Serum samples were collected before inoculation and at approximately days 2, 7, 14, 28, and 180 postinoculation.
Definitions
Norwalk virus infection was defined as fecal virus excretion (by antigen enzyme immunoassay [EIA] or RT-PCR) or a ≥4-fold increase in serum antibody titer measured by antibody EIA (from preinoculation to 28 days postinoculation). Viral gastroenteritis was defined as moderate diarrhea alone (>200 g watery [immediately takes the shape of the container] feces) or as 1 episode of vomiting with at least 1 other symptom (abdominal cramps/pain, nausea, bloating, loose feces, fever ≥37.6°C, myalgia, or headache) for any continuous 24-hour period.
Laboratory Studies
Norwalk virus-specific antigen and antibody EIAs were performed as described previously [5, 13, 19] . Norwalk-specific serum immunoglobulin G (IgG) and immunoglobulin A (IgA) assays were determined using a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) [15] , and HBGA blocking antibody responses were measured as previously described [16] . H type 1 glycan (Glycotech) was used for viruslike particle capture for the first 35 enrollees and H type 3 glycan (Glycotech) for the last 22 participants. Quantitative real-time and immunomagnetic capture RT-PCR assays were performed as described previously for measuring Norwalk virus excretion in fecal samples [13] . Quantitative real-time RT-PCR was also used to measure virus in vomitus and to quantify virus in the challenge pool. Secretor status was determined by measuring the presence of histoblood group antigens in a salivary sample, with persons having A, B, or Lewis b (Le b ) being scored as secretor positive [16] . Some secretor-negative subjects were enrolled in each of the first 4 groups before it was discovered that the monoclonal antibody (anti-Le were used to identify secretor-positive subjects [16] .
Statistical Analysis
Parametric data were compared with Student t test and nonparametric data with Wilcoxon rank-sum or Kruskal-Wallis tests. Categorical variables were analyzed using χ 2 or Fisher exact tests. Linear regression was used to assess the effect of dosage on time to the development of gastroenteritis, and logistic regression was used to determine the HID 50 . The 95% confidence intervals (CIs) for the HID 50 were calculated based on the Fieller theorem.
RESULTS
Demographics
Fifty-seven persons were enrolled in the study ( Table 1 ). The median age was 27 years, and 54% of the participants were male. Eight persons who received a virus-containing inoculum were subsequently found to be secretor negative. Three persons dropped out of the study early, 1 after the day 7 follow-up and 2 after the day 30 follow-up; all 3 had sufficient data available to be included in the determination of the HID 50 .
Infection Status
Twenty-one persons were infected with Norwalk virus (Table 2) ; all were secretor positive and either blood group O or A. None of the 8 placebo recipients, none of the 8 nonsecretors, and none of the 6 persons who were blood group B or AB and received virus became infected. The HID 50 for blood group O and A persons is estimated to be 3.3 RT-PCR units (95% CI, 1.1-9.4); the estimate is higher ( 
Clinical Illness and Safety
All but 1 infected person had symptoms during the 4 days after inoculation, with nausea, abdominal cramps, and malaise being the most common (Table 3 ). All 14 of the persons who fulfilled the definition of gastroenteritis vomited at least once and 7 had watery diarrhea. Symptoms were present in 6 of the 7 subjects who did not fulfill the definition of gastroenteritis, 2 of whom had 1 episode of watery fecal sample that weighed <100 g. The time from inoculation to onset of vomiting or watery diarrhea (Table 4) increased with decreasing inoculum dosage (P = .001, linear regression). Thus, the median onset in the lowestdosage groups (4.8 RT-PCR units or less) was 11 hours later than that in the highest-dosage group (4800 RT-PCR units). Increasing inoculum dosage also was associated with increasing duration of illness (P = .04, linear regression).
The symptoms and signs associated with participation in the study were largely those of viral gastroenteritis. Severe symptoms included 3 episodes of severe nausea, 2 episodes of severe diarrhea, and 1 episode of severe headache in 5 persons, all of 
a Three secretor-negative persons in the virus group were blood group A (n = 2) or B (n = 1). whom had viral gastroenteritis. The largest 24-hour volume loss was 3.6 L (1.8 L watery diarrhea and 1.7 kg vomitus), but no other subject had >2 L output in 24 hours and none required intravenous volume repletion. All but 1 of the persons who vomited subsequently received between 1 and 3 doses of ondansetron to control nausea. There was 1 serious adverse event during the study and it was assessed as unrelated. A placebo recipient developed a partial retinal detachment 74 days after receipt of study product.
Virology
All but 1 of the persons who were infected with Norwalk virus had virus present by RT-PCR in at least 5 different fecal samples; 1 person did not return fecal samples after study day 3 and the last 2 fecal samples collected were positive. One subject (number 731) had a solid stool sample approximately 20 hours after illness onset without virus being identified in the sample; the first virus-positive fecal sample was identified approximately 40 hours after resolution of symptoms. For all other ill subjects, virus was present in all tested samples collected during illness. The duration of shedding for persons from whom stool samples were collected for at least 4 weeks ranged from 6 days to 55 days. Excluding the subject who did not provide stool samples beyond the first 3 days after inoculation, the median duration was 29 days in persons who fulfilled the definition of gastroenteritis compared to 19 days for those without gastroenteritis (P = .14, Wilcoxon rank-sum test). Similarly, virus shedding duration for persons who received a dose of 48 or 4800 RT-PCR units was 29 days compared with 20 days for those who received a lower inoculum dosage (P = .12, Wilcoxon rank-sum test). The maximal fecal virus concentration was greater in persons with viral gastroenteritis compared to those without (geometric mean titer [GMT], 160 billion vs 10 billion gEq/mL, respectively, P = .005, Student t test), although no differences were observed in GMT maximal fecal virus concentration based upon inoculum dosage received.
Virus antigen was identified in fecal samples of 18 of 21 infected persons; 1 person with gastroenteritis and 2 persons without viral gastroenteritis had no antigen-positive stool samples. All antigen-positive stool samples were also positive by RT-PCR. The median duration of antigen-positive stools was 5 days (range, 1-9 days). The duration of antigen-positive fecal samples was similar among ill and nonill persons (5 vs 6 days, respectively, P = .29, Wilcoxon rank-sum test).
Twenty-seven specimens of emesis were collected from 12 ill subjects; specimens from 2 ill participants were not obtained. Norwalk virus was identified in 15 (56%) of the specimens, with a range in titer from <2200 to 12 million gEq/mL. The median concentration of virus-positive samples was 41 thousand (interquartile range, 3800-240 000) gEq/mL.
Serology
All infected persons had at least a 16-fold increase in serum pan-enzyme-linked immunosorbent assay antibody titer at some timepoint following infection (Table 5) . None had a 4-fold rise by day 2 after inoculation, but 12 (57%) had a rise by day 7 postinoculation. All infected persons had a rise on days 14 and 28 after inoculation (see Supplementary Table 1; 1 subject was lost to follow-up after day 7 but had a 32-fold rise on this day). The peak geometric mean fold rise occurred at day 28, and antibody levels at 6 months were still higher than at baseline. Similar results were seen for other serological assays (Table 5) , although serum IgA antibody levels rose sooner and peaked earlier (at 14 days). The prechallenge serum HBGA blocking antibody level was significantly lower among those who developed gastroenteritis (Supplementary Figure 1 , P = .006, Wilcoxon rank-sum test); the same was not observed for prechallenge serum antibody levels measured using the other serological assays.
DISCUSSION
Dose-response data are an important component in the generation of quantitative risk assessments for infectious agents [20] . There are limited data examining the quantitative estimates of norovirus exposure to infection risk [18, 21, 22] and only 1 previous report evaluated the HID 50 [8] . In the current study, we found that the HID 50 was approximately 1320 gEq for secretorpositive persons who were blood type O or A. We previously have observed that persons who express blood group B are less likely to develop disease following Norwalk virus exposure [23] .
In this study, none of the persons who expressed blood group B became infected. However, if the data from these persons are included in the calculation of the HID 50 , the estimate increases to 2800 gEq. Teunis and colleagues determined the HID 50 of Norwalk virus in an experimental human infection model while making assumptions and adjustments for virus aggregation; they reported an HID 50 estimate that ranged from 18 to 1015 gEq depending on their modeling assumptions [8] . Interestingly, no person in their study administered a dosage of 324 gEq or less was infected, and only 3 of 9 administered a dosage of 3240 gEq became infected. In addition to the potential impact of aggregation described by Teunis et al [8] , another potential reason for the number of gEq to be higher than the estimated infective dose is the presence of noninfectious genomes that result from the error-prone viral RNA-dependent RNA polymerase. The particle to plaque-forming unit (PFU) for murine norovirus has been reported to range from 100 to 10 000 gEq [24, 25] , which is similar to that reported for picornaviruses (up to 1000 gEq/PFU) [26] . Another factor that could affect virus infectivity is the host's preexisting immunity [17] such that a larger amount of virus is required to infect persons with some immunity. We were not able to observe an impact of preexisting immunity on susceptibility to infection, although we were able to confirm our prior observation of an effect of serum levels of HBGA-blocking antibody levels on the development of gastroenteritis [16] .
The inoculum dose did not have an effect on the frequency of the development of gastroenteritis among those who were infected (ie, illness was as likely to develop in those administered lower dosages as in those who received higher dosages). However, higher inoculum dosages were associated with shorter incubation times and higher peak virus shedding. Similar inverse relationships between inoculum dosage and incubation period have been noted for other enteric pathogens (Salmonella typhosa, Vibrio cholerae) in human experimental infection models [27, 28] .
Norovirus transmission has been associated with vomiting events [29, 30] , and norovirus has been observed in vomitus samples and oral mouthwash samples [31, 32] . Our study provides an estimate of the frequency and the first quantitative determination of levels of virus contamination of vomitus. Viral RNA was observed less frequently in vomitus than in the feces, and viral levels in vomitus samples were much lower than observed in stool. Nevertheless, 1 mL of vomitus was found to contain as much as 9000 HID 50 of virus. These levels of virus emphasize the importance of disinfecting sites contaminated by vomitus.
Human experimental infection studies that enhance the likelihood that an exposed person will become infected include host genetic background (eg, secretor status), virus strain (eg, genotype), host immunity (eg, as measured by serum HBGAblocking antibody), and level of exposure. These factors can also influence disease manifestations (eg, preexisting immunity) and incubation period, as well as the level and duration of virus shedding. The quantitative assessments made in this and similar studies should be useful for future hazard analyses.
